Región Metropolitana de Santiago
Este organismo compró $35.329.096.472 en 11.633 órdenes de compra , sobre todo en Medicamentos y productos farmacéuticos / Medicamentos anti infecciosos / Medicamentos antivirales y le compró principalmente a Sur Medical SpA.
238 meses con data · color por monto (sqrt scale)
| Año | Ene | Feb | Mar | Abr | May | Jun | Jul | Ago | Sep | Oct | Nov | Dic | Total año |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
| $1367,1 M |
| 2025 | $2402,7 M |
| 2024 | $2107,2 M |
| 2023 | $2816,8 M |
| 2022 | $1338 M |
| 2021 | $1018,6 M |
| 2020 | $888,8 M |
| 2019 | $901,2 M |
| 2018 | $1471,2 M |
| 2017 | $786,1 M |
| 2016 | $14,2 mil M |
| 2015 | $919,8 M |
| 2014 | $428,8 M |
| 2013 | $340,8 M |
| 2012 | $359,5 M |
| 2011 | $701,4 M |
| 2010 | $913,7 M |
| 2009 | $590,7 M |
| 2008 | $571,8 M |
| 2007 | $1180,7 M |
| 2006 | $34,7 M |
238 períodos con data
Fuente: Agregaciones mensuales sobre OCs ingeridas
10 contrapartes
Fuente: Tabla top_contrapartes_comprador
| Código | Fecha | Proveedor | Estado | Monto |
|---|---|---|---|---|
| 2980-134-AG26 | 16-03-2026 | Novartis Chile S.A. | Recepcion Conforme | $3.923.839 |
| 2980-135-AG26 | 16-03-2026 | Astrazeneca S.A. | Recepcion Conforme | $4.955.084 |
| 2980-136-AG26 | 16-03-2026 | Novartis Chile S.A. | Recepcion Conforme | $2.697.646 |
| 2980-137-AG26 | 16-03-2026 | Novartis Chile S.A. | Recepcion Conforme | $1.582.714 |
| 2980-138-AG26 | 16-03-2026 | Johnson y Johnson de Chile S.A. | Recepcion Conforme | $2.623.950 |
| 2980-139-AG26 | 16-03-2026 | Novartis Chile S.A. | Recepcion Conforme | $2.358.190 |
| 2980-140-AG26 | 16-03-2026 | Scienza Chile SpA | Recepcion Conforme | $5.414.500 |
| 2980-118-AG26 | 11-03-2026 | Novartis Chile S.A. | Recepcion Conforme | $5.596.944 |
| 2980-120-AG26 | 11-03-2026 | Lyp Group SpA | Recepcion Conforme | $3.460.520 |
| 2980-119-AG26 | 10-03-2026 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $352.240 |
| 2980-115-AG26 | 04-03-2026 | Servitech Chile SpA | Recepcion Conforme | $122.376 |
| 2980-116-AG26 | 04-03-2026 | Novartis Chile S.A. | Recepcion Conforme | $5.596.944 |
| 2980-117-AG26 | 04-03-2026 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $1.051.960 |
| 2980-114-AG26 | 04-03-2026 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $2.440.095 |
| 2980-83-AG26 | 24-02-2026 | Synthon Chile Limitada | Recepcion Conforme | $1.591.363 |
| 2980-77-AG26 | 18-02-2026 | Astrazeneca S.A. | Recepcion Conforme | $4.955.084 |
| 2980-78-AG26 | 18-02-2026 | Abbvie Productos Farmaceuticos Limitada | Recepcion Conforme | $1.392.300 |
| 2980-80-AG26 | 18-02-2026 | Scienza Chile SpA | Recepcion Conforme | $5.414.500 |
| 2980-81-AG26 | 18-02-2026 | Novartis Chile S.A. | Recepcion Conforme | $3.537.285 |
| 2980-82-AG26 | 18-02-2026 | Astrazeneca S.A. | Recepcion Conforme | $4.955.084 |
| 2980-84-AG26 | 18-02-2026 | Galenicum Health Chile SpA | Recepcion Conforme | $3.426.343 |
| 2980-85-AG26 | 18-02-2026 | Tecnofarma S.A. | Recepcion Conforme | $926.868 |
| 2980-86-AG26 | 18-02-2026 | Johnson y Johnson de Chile S.A. | Recepcion Conforme | $6.669.902 |
| 2980-87-AG26 | 18-02-2026 | Bayer S.A. | Recepcion Conforme | $6.735.909 |
| 2980-89-AG26 | 18-02-2026 | Gador Limitada | Recepcion Conforme | $2.332.400 |
| 2980-90-AG26 | 18-02-2026 | Astrazeneca S.A. | Recepcion Conforme | $3.795.524 |
| 2980-91-AG26 | 18-02-2026 | Laboratorios Andromaco S.A. | Recepcion Conforme | $5.255.040 |
| 2980-92-AG26 | 18-02-2026 | Johnson y Johnson de Chile S.A. | Recepcion Conforme | $6.669.902 |
| 2980-93-AG26 | 18-02-2026 | Johnson y Johnson de Chile S.A. | Recepcion Conforme | $6.669.902 |
| 2980-94-AG26 | 18-02-2026 | Productos Farmoquimicos Roche Limitada | Recepcion Conforme | $5.617.485 |
